(NA )
No "vaccine" for COVID-19 HAS COMPLETED PHASE 3
See the "estimated" dates of some of the trade names.
PEDIATRIC PFIZER Phase 1, 2 and 3 not started. Estimated Completion Date:
MAY 5, 2026
Souce
Brief Summary: This is a Phase 1/2/3 study in healthy children and young adults. Dependent upon safety and/or immunogenicity data generated during the course of this study, and the resulting assessment of benefit-risk, the safety, tolerability, and immunogenicity of BNT162b2 in participants <6 months of age may subsequently be evaluated.
PFIZER REINFORCEMENT ADULTS Phase 3.
Estimated Completion Date:
SEPTEMBER 5, 2023
SINOPHARM ADULTS Phase 3. Estimated completion date:
JULY 15, 2022
ASTRAZENECA ADULTS Phase 3. Estimated completion date:
FEBRUARY 14, 2023
MODERN Phase 3. Estimated completion date:
OCTOBER 27, 2022
SINOVAC PEDIATRIC Phase 3. Estimated completion date:
APRIL 1, 2023
CANSINO ADULTS Phase 3. Estimated completion date:
JANUARY 30, 2022 (Which is false because they are still recruiting)
COVAXIN ADULTS phase 3. Estimated completion date:
DECEMBER 2022